Major equity grants to NeoGenomics (NEO) CEO Anthony P. Zook

Rhea-AI Filing Summary

NeoGenomics Inc. reported that Chief Executive Officer Anthony P. Zook received new equity awards. On March 1, 2026, he was granted 675,676 stock options and 406,918 restricted stock units at no cost per unit. The options are premium-price awards, with the exercise price set at 110% of the closing share price on February 27, 2026. Both the options and RSUs vest ratably over the first three anniversaries of the grant date, tying most of the value to multi‑year service and performance. Once vested, the underlying common shares are not subject to expiration. Footnotes also reference earlier premium-price grants on April 1, 2025, indicating a continuing emphasis on performance-oriented, at-risk compensation for the CEO.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zook Anthony P.

(Last) (First) (Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS FL 33912

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								38,066	D
Common Stock								18,900	I	Amended and Restated Anthony P. Zook Living Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.81(1)	03/01/2026		A		675,676		(2)	03/01/2036	Common Stock	675,676	$0	675,676	D
Restricted Stock Unit	$0	03/01/2026		A		406,918		(3)	(4)	Common Stock	406,918	$0	406,918	D
Stock Option (Right to Buy)	$14.82							08/10/2024	08/10/2033	Common Stock	8,353		8,353	D
Stock Option (Right to Buy)	$13.71							06/01/2025	06/01/2034	Common Stock	8,672		8,672	D
Stock Option (Right to Buy)	$10.44(5)							(6)	04/01/2035	Common Stock	729,927		729,927	D
Restricted Stock Unit	$0							(7)	(4)	Common Stock	421,496		421,496	D

Explanation of Responses:

1. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.

2. On March 1, 2026, Mr. Zook was granted 675,676 stock options. The options vest ratably over the first three anniversary dates of the grant date.

3. On March 1, 2026, Mr. Zook was granted 406,918 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

4. Once vested, the shares of common stock are not subject to expiration.

5. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.

6. On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date.

7. On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did NeoGenomics (NEO) report for CEO Anthony P. Zook?

NeoGenomics reported that CEO Anthony P. Zook received equity awards on March 1, 2026. He was granted stock options and restricted stock units that vest over three years, reflecting performance-oriented, at-risk executive compensation rather than open‑market share purchases or sales.

How many stock options and RSUs were granted to the NeoGenomics (NEO) CEO?

On March 1, 2026, Anthony P. Zook was granted 675,676 stock options and 406,918 restricted stock units. These awards vest in three equal annual installments, meaning the full benefit is realized only if he remains with NeoGenomics over the multi‑year vesting period.

What does premium-price stock option mean in the NeoGenomics (NEO) Form 4?

The filing states Zook’s stock options were granted as premium-price options, with exercise prices set at 110% of the relevant closing share price. This structure only creates value if NeoGenomics’ stock rises meaningfully above that already-elevated strike level after grant, aligning incentives with shareholder gains.

How do the NeoGenomics (NEO) CEO’s new equity awards vest over time?

Both the March 1, 2026 stock options and restricted stock units vest ratably over the first three anniversary dates of the grant. One-third of each award vests each year, encouraging multi‑year leadership continuity and linking a substantial portion of compensation to long‑term company performance.

Are the NeoGenomics (NEO) CEO’s vested shares subject to expiration?

The filing notes that once the restricted stock units vest into common shares, those shares are not subject to expiration. This means vested shares can be held indefinitely, though any future sale decisions would be subject to trading windows, regulations, and potential additional company or insider policies.

What earlier equity grants to the NeoGenomics (NEO) CEO are referenced?

Footnotes reference April 1, 2025 grants of 729,927 premium-price stock options and 421,496 restricted stock units to Anthony P. Zook. These prior awards also vest over three years, underscoring a consistent approach of multi‑year, performance-linked equity incentives in NeoGenomics’ executive compensation program.